0001569769-23-000007.txt : 20231016 0001569769-23-000007.hdr.sgml : 20231016 20231016160632 ACCESSION NUMBER: 0001569769-23-000007 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231013 FILED AS OF DATE: 20231016 DATE AS OF CHANGE: 20231016 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Soni Manmeet Singh CENTRAL INDEX KEY: 0001569769 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36866 FILM NUMBER: 231327403 MAIL ADDRESS: STREET 1: C/O PHARMACYCLICS, INC. STREET 2: 995 EAST ARQUES AVE CITY: SUNNYVALE STATE: CA ZIP: 94085 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Summit Therapeutics Inc. CENTRAL INDEX KEY: 0001599298 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2882 SAND HILL ROAD STREET 2: SUITE 106 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 617-514-7149 MAIL ADDRESS: STREET 1: 2882 SAND HILL ROAD STREET 2: SUITE 106 CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: Summit Therapeutics plc DATE OF NAME CHANGE: 20150219 FORMER COMPANY: FORMER CONFORMED NAME: Summit Corp plc DATE OF NAME CHANGE: 20140205 4 1 wk-form4_1697486782.xml FORM 4 X0508 4 2023-10-13 0 0001599298 Summit Therapeutics Inc. SMMT 0001569769 Soni Manmeet Singh C/O SUMMIT THERAPEUTICS INC. 2882 SAND HILL ROAD, SUITE 106 MENLO PARK CA 94025 1 1 0 0 Chief Operating Officer 0 Common Stock 2023-10-13 4 P 0 2976190 1.68 A 2976190 D Stock Option (right to buy) 1.68 2023-10-13 4 A 0 14000000 A 2033-10-13 Common Stock 14000000 14000000 D The Issuer entered into a securities purchase agreement with the Reporting Person, pursuant to which the Issuer agreed to issue and sell to the Reporting Person shares of the Issuer's Common Stock at a per share purchase price equal to $1.68. The option was granted on October 13, 2023. The shares underlying the option shall vest in four equal annual installments, with the first such installment occurring on October 13, 2024. Note this does not include an additional 14,000,000 options which were granted on October 13, 2023 and are subject to the satisfaction of performance conditions based on market capitalization and revenue targets. Not applicable. /s/ Manmeet Soni 2023-10-16